Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer

Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment for metastatic pancreas cancer. It is unclear, however, whether patients who had received irinotecan derive benefit. Medical records of metastatic pancreas cancer patients who had received irinotecan and then Nal-IRI were review...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2021-03, Vol.21 (2), p.379-383
Hauptverfasser:	Smith, Caleb J., Bekaii-Saab, Tanios S., Cook, Kathryn D., Eiring, Rachel A., Halfdanarson, Thorvardur R., Hanna, Mina, Jin, Zhaohui, Jochum, Jacob A., Ma, Wen Wee, Mitchell, Jessica L., Pitot, Henry C., Jatoi, Aminah
Format:	Artikel
Sprache:	eng
Schlagworte:	Cancer therapies Chemotherapy Confidence intervals Decision making Guidelines Irinotecan Liposomal Medical records Metastases Metastasis Pancreas Pancreas cancer Pancreatic cancer Patients Survival
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!